三鑫医疗(300453) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥406,794,256.65, representing a 2.76% increase year-over-year[4] - Net profit attributable to shareholders was ¥69,861,041.47, up 13.29% compared to the same period last year[4] - The basic earnings per share increased by 15.08% to ¥0.1366 for the current period[4] - Total operating revenue for the current period reached ¥1,167,602,224.43, an increase of 7.4% compared to ¥1,082,325,012.30 in the previous period[21] - Net profit for the current period was ¥204,312,790.12, representing a growth of 11.4% from ¥183,343,938.37 in the previous period[22] - Basic earnings per share increased to ¥0.3573 from ¥0.3232, marking a rise of 10.6%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,310,054,116.09, reflecting a 3.93% increase from the end of the previous year[4] - Total assets reached ¥2,310,054,116.09, compared to ¥2,222,709,961.44, indicating a growth of 3.9%[19] - Total liabilities increased to ¥834,279,303.35 from ¥814,055,748.31, reflecting a rise of 2.7%[19] - Non-current assets totaled ¥1,480,068,112.76, up from ¥1,398,754,616.01, showing an increase of 5.8%[19] - Current liabilities decreased slightly to ¥558,402,423.00 from ¥577,595,822.70, a decline of 3.4%[19] Cash Flow - Operating cash inflow for the current period reached ¥1,354,172,234.70, an increase of 11.6% compared to ¥1,212,962,998.57 in the previous period[24] - Net cash flow from operating activities was ¥325,422,401.90, slightly up from ¥323,591,496.43 in the previous period[24] - Cash inflow from investment activities totaled ¥488,203,748.46, significantly higher than ¥154,621,615.16 in the previous period[25] - Net cash flow from investment activities was -¥272,215,709.56, worsening from -¥224,909,519.62 in the previous period[25] - Cash inflow from financing activities was ¥81,840,000.00, down from ¥168,434,775.00 in the previous period[25] - Net cash flow from financing activities was -¥199,338,269.68, compared to -¥186,197,100.44 in the previous period[25] - The ending balance of cash and cash equivalents was ¥135,355,790.28, up from ¥111,439,210.26 in the previous period[25] Investments - The company reported a significant increase in investment income of 1339.59%, totaling ¥3,513,977.61, primarily due to increased financial management returns[8] - The company reported an investment income of ¥3,513,977.61, recovering from a loss of ¥283,479.34 in the previous period[22] - The company received ¥479,831,813.95 from investment recoveries, a substantial increase from ¥152,241,110.00 in the previous period[25] - The company paid ¥570,471,075.00 for investments, significantly higher than ¥223,000,000.00 in the previous period[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,101[11] - The largest shareholder, Peng Yixing, holds 32,231,511 shares, representing a significant portion of the company's equity[12] - The company has a total of 165,183,790 shares subject to lock-up agreements, with 2,831,750 shares released during the period[15] - The company has a total of 96,694,533 shares under lock-up for Peng Yixing, which will remain locked for 75% of the term[14] - The company has not reported any changes in the status of its major shareholders participating in margin trading activities[12] Other Financial Metrics - The company’s weighted average return on equity was 5.15%, an increase of 0.41% from the previous year[4] - The company received government subsidies amounting to ¥20,147,396.69, a 73.66% increase compared to the previous year[8] - Research and development expenses for the current period were ¥50,894,409.75, compared to ¥44,733,074.43, an increase of 13.4%[21] - Cash and cash equivalents decreased by 48.67% to ¥148,770,600.97, mainly due to increased purchases of financial products[9] - The company reported a decrease in cash and cash equivalents, with a balance of ¥148,770,600.97 compared to ¥289,846,781.19 at the beginning of the period, reflecting a decline of approximately 48.7%[17] - Trading financial assets increased significantly to ¥321,713,269.90 from ¥178,481,242.87, marking an increase of about 80.0%[17] - Inventory levels rose to ¥215,956,705.08 from ¥195,673,582.44, indicating an increase of approximately 10.4%[17] - Accounts receivable slightly decreased to ¥81,576,277.11 from ¥83,256,881.36, a decline of about 2.0%[17] - The company’s total current assets include various components, with a notable increase in prepayments to ¥15,806,640.89 from ¥13,223,949.61, an increase of about 19.5%[17] - The company’s total receivables financing increased to ¥7,373,398.77 from ¥2,770,415.37, reflecting a growth of approximately 165.5%[17]